TSX runs higher on rate cut expectations
Monogram Technologies Inc. (NASDAQ:MGRM), currently trading at $5.63 and near its 52-week high of $6.02, on Wednesday amended its previously announced merger agreement with Zimmer Biomet Holdings, Inc., according to a statement filed with the Securities and Exchange Commission. The company, with a market capitalization of $216.57 million, has seen its stock surge 141.63% over the past six months.
The amendment, dated August 27, 2025, modifies the definition of “Permitted Transfer” in the form of Contingent Value Rights (CVR) Agreement attached to the original merger agreement. The change was made in response to a verbal comment from the Securities and Exchange Commission.
Monogram and Zimmer Biomet originally entered into the merger agreement on July 14, 2025. Under the terms of the agreement, Honey Badger Merger Sub, Inc., a wholly owned subsidiary of Zimmer Biomet, will merge with and into Monogram Technologies. Monogram will continue as the surviving corporation and become a wholly owned subsidiary of Zimmer Biomet Holdings.
The amendment to the merger agreement was included as Exhibit 2.1 in the SEC filing. The company’s common stock trades on The Nasdaq Stock Market under the symbol MGRM.
This article is based on a press release statement included in Monogram Technologies’ recent SEC filing.
In other recent news, Monogram Technologies has been in the spotlight due to several significant developments. The company announced its acquisition by Zimmer Biomet Holdings for approximately $177 million in equity value. As part of the agreement, Zimmer Biomet will pay $4.04 per share in cash to Monogram shareholders, with an additional potential payout through a non-tradeable contingent value right if certain milestones are met by 2030. Monogram also addressed shareholder inquiries by releasing a set of FAQs about the acquisition.
Additionally, Monogram terminated its Exclusive License Agreement with the Icahn School of Medicine at Mount Sinai, reverting all rights and licenses back to Mount Sinai. As part of the settlement, Monogram will pay Mount Sinai $4 million, consisting of $500,000 in cash and Series E Redeemable Perpetual Preferred Stock valued at $3.5 million. Furthermore, Monogram announced the mandatory conversion of its Series D Convertible Cumulative Preferred Stock. These recent developments highlight a period of transition and restructuring for Monogram Technologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.